Denosumab biosimilar - Intas Pharmaceuticals

Drug Profile

Denosumab biosimilar - Intas Pharmaceuticals

Latest Information Update: 16 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intas Pharmaceuticals
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies; Osteoporosis therapies
  • Mechanism of Action RANK ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Postmenopausal osteoporosis

Most Recent Events

  • 30 Apr 2018 Intas Pharmaceuticals completes a phase III trial in Postmenopausal osteoporosis (In adults, In the elderly) in India (SC) (CTRI2015-07-006065)
  • 31 Aug 2016 Preclinical trials in Postmenopausal osteoporosis in India (SC) before August 2016
  • 31 Aug 2016 Intas Pharmaceuticals plans a phase III trial for Postmenopausal osteoporosis (In adults, In the elderly) in India (CTRI2015-07-006065)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top